Healthcare (Prescription Drugs)

failed · Wisconsin · Senate Mar 23, 2026

SB 703: Relating to: plan sponsors’ right to access claims data.

SB 703 requires health insurers, administrators, and pharmacy benefit managers (PBMs) to provide large employer plan sponsors (those covering 50+ employees) with full access to their health claims data. Plan sponsors own this data and can request specific details - like itemized billing for high-cost claims ($25,000+ medical, $10,000+ pharmacy), payment histories, pharmacy rebates, and administrative fees - within 7 business days of a written request. Insurers and PBMs must deliver this data electronically in usable formats, and cannot sell the data without the plan sponsor’s and individual’s permission. The bill directly affects large employers managing health benefits and the companies providing those benefits, ensuring transparency in how claims data is handled and shared.

Topics ✓ HealthcareSupports HealthcareRequires insurers/PBMs to provide large employers full access to health claims data for cost transparency and management, enhancing employer plan oversight and potentially reducing costs for covered employees.90% confidence

Sub-Topics Prescription Drugs

Track

failed · Wisconsin · Senate Mar 23, 2026

SB 534: Relating to: regulating medical cannabis, the prescription drug monitoring program, and providing a penalty. (FE)

SB 534 creates an Office of Medical Cannabis Regulation within the Department of Health Services to oversee medical cannabis programs. It defines "medical cannabis product" consistently across statutes and prohibits courts from considering lawful medical cannabis use or registry status when making child custody decisions, except in cases where a child accesses the products. The bill also amends provisions related to prescription drug monitoring and clarifies that local ordinances cannot prosecute for marijuana possession under specific conditions. These changes primarily affect patients using medical cannabis, courts handling custody cases, and state agencies managing cannabis and drug monitoring programs.

Topics ✓ HealthcareSupports HealthcareCreates Health Department office for medical cannabis regulation and prohibits courts from penalizing lawful use in custody cases, advancing patient access and rights within healthcare services.95% confidence

Sub-Topics Prescription Drugs

Track

signed · Wisconsin · Senate Mar 28, 2025

SB 68: Relating to: the prescription drug monitoring program. (FE)

SB 68 amends Wisconsin's prescription drug monitoring program to require healthcare practitioners (like doctors and pharmacists) to review a patient's prescription history before issuing new prescriptions for certain medications. This review must occur before prescribing, and can be done by the practitioner or their agent following standard practices. The requirement applies until April 1, 2030, after which the rule expires. The bill updates existing statutes to clarify this review process and sets a specific end date for the mandate.

Topics ✓ HealthcareSupports HealthcareRequires healthcare practitioners to review prescription history before issuing new prescriptions, enhancing patient safety and preventing misuse within healthcare practices.90% confidence

Sub-Topics Prescription Drugs

passed · Wisconsin · Assembly Mar 23, 2026

AB 43: Relating to: permitting pharmacists to prescribe certain contraceptives, extending the time limit for emergency rule procedures, providing an exemption from emergency rule procedures, granting rule-making authority, and providing a penalty. (FE)

Assembly Bill 43 permits pharmacists to prescribe and dispense hormonal contraceptive patches and self-administered oral hormonal contraceptives to individuals aged 18 and older. Pharmacists must adhere to new rules, including requiring patients to complete a self-assessment questionnaire and undergo a blood pressure screening. The bill also mandates that pharmacists report prescriptions to the patient's primary care provider, provide a written record, and carry malpractice liability insurance. Furthermore, it ensures these contraceptives are covered under Medical Assistance when prescribed by pharmacists and grants the Pharmacy Examining Board authority for related rule-making.

Topics ✓ HealthcareSupports HealthcareExpands contraceptive access via pharmacists, improving reproductive healthcare availability without requiring physician visits per bill's core provisions.90% confidence

Sub-Topics Prescription Drugs Primary Care

Track

failed · Wisconsin · Assembly Mar 23, 2026

AB 68: Relating to: the prescription drug monitoring program. (FE)

AB 68 modifies Wisconsin's prescription drug monitoring program (PDMP) by requiring healthcare practitioners to review a patient's PDMP records before prescribing controlled substances. This applies to all prescribers of such medications and expires on April 1, 2030. The bill also extends the deadline for certain program requirements from October 30, 2025, to October 30, 2030. It does not create new obligations but adjusts existing review timelines for the PDMP. The bill was referred to committee but ultimately "laid on the table" in March 2025.

Topics ✓ HealthcareSupports HealthcareRequires prescribers to review PDMP records before prescribing controlled substances, aiming to prevent drug abuse and promote safe prescribing practices, directly supporting public health and patient safety in healthcare.85% confidence

Sub-Topics Prescription Drugs

Track

failed · Wisconsin · Assembly Mar 23, 2026

AB 173: Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

AB 173 regulates pharmacy benefit managers (PBMs) by requiring them to disclose formulary details and drug costs to health plans and patients before enrollment. It prohibits PBMs or insurers from penalizing patients for choosing specific pharmacies within a network or charging different fees for the same pharmacy services. The bill also mandates advance written notice (at least 90 days) to patients when drugs are removed from formularies or moved to higher-cost tiers, including exception request procedures. These changes directly affect PBMs, health insurance plans, and patients covered by those plans, aiming to increase transparency and choice in prescription drug coverage.

Topics ✓ HealthcareSupports HealthcareRegulates PBMs for transparency, protects patient choice, mandates formulary change notices - improves access and rights per bill's disclosure/penalty prohibitions.95% confidence

Sub-Topics Insurance Prescription Drugs

Track

failed · Wisconsin · Assembly Mar 23, 2026

AB 547: Relating to: regulating medical cannabis, the prescription drug monitoring program, and providing a penalty. (FE)

AB 547 establishes a new Office of Medical Cannabis Regulation within Wisconsin's Department of Health Services to oversee medical cannabis programs. It defines "medical cannabis product" consistently across state laws and adds protections preventing courts from denying child custody based solely on lawful medical cannabis use or registry enrollment. The bill also updates local ordinances to clarify restrictions on marijuana possession, ensuring penalties don't apply to medical cannabis users under specific circumstances. These changes aim to create a clearer regulatory framework while addressing legal inconsistencies in existing statutes.

Topics ✓ HealthcareSupports HealthcareEstablishes medical cannabis regulatory office within health agency, defines products consistently, and protects patients from custody denial due to lawful use, advancing healthcare access and rights.95% confidence

Sub-Topics Prescription Drugs

Track

failed · Wisconsin · Assembly Mar 23, 2026

AB 62: Relating to: health care costs omnibus, granting rule-making authority, making an appropriation, and providing a penalty. (FE)

AB 62 establishes a Prescription Drug Affordability Review Board to address prescription drug costs. The board, with members representing pharmaceutical companies, health insurers, healthcare providers, and the public, must meet quarterly and avoid conflicts of interest. Key provisions include creating a $500,000 annual grant program for healthcare providers to develop tools showing patients the cost of prescriptions (Section 601.415), launching a diabetes medication pilot project (Section 601.41), and repealing a section requiring copayments for certain Medicaid services (Section 7). This bill directly affects insurers, pharmacies, drug manufacturers, and healthcare providers who must disclose drug costs to patients.

Topics ✓ Budget & TaxesSupports Budget & TaxesBill appropriates $500,000 annually for healthcare cost transparency tools, directly funding a public service initiative under state budget management.95% confidence ✓ HealthcareSupports HealthcareEstablishes Prescription Drug Affordability Review Board, funds cost transparency tools ($500k grants), and launches diabetes medication pilot to lower healthcare costs.95% confidence

Sub-Topics Appropriations Medicaid Prescription Drugs

Track

failed · Wisconsin · Senate Mar 23, 2026

SB 203: Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

SB 203 regulates pharmacy benefit managers (PBMs) by requiring them to pay pharmacies within 30 days for electronic claims and 60 days for paper claims. It mandates that claims for 340B drugs (federally discounted medications) include specific identifiers for processing. The bill also prohibits PBMs from forcing pharmacies to join multiple networks or penalizing them for declining to join such networks. These provisions directly affect PBMs, pharmacies, and prescribers within the state’s health insurance system.

Topics ✓ HealthcareSupports HealthcareRegulates PBMs to ensure timely pharmacy payments, prevent anti-competitive practices, and improve access to medications - directly strengthening healthcare delivery and patient access.95% confidence

Sub-Topics Insurance Prescription Drugs

Track

failed · Wisconsin · Senate Mar 23, 2026

SB 50: Relating to: health care costs omnibus, granting rule-making authority, making an appropriation, and providing a penalty. (FE)

SB 50 establishes a Prescription Drug Affordability Review Board to address prescription drug costs, requiring it to meet quarterly and include balanced representation from pharmaceutical manufacturers, health insurers, healthcare providers, and the public. The bill allocates $500,000 annually for state operations related to this board and funds a pilot project to create value-based diabetes medication arrangements with pharmacy benefit managers. It also modifies Medicaid copayment rules to prevent providers from denying care due to inability to pay copays, while creating a new tool for prescribers to disclose drug costs to patients. Additionally, the bill authorizes partnerships with out-of-state drug repositories and allows pharmacists to count free clinic volunteer hours toward continuing education requirements.

Topics ✓ Budget & TaxesSupports Budget & TaxesAllocates $500,000 annually for Prescription Drug Board operations and funds diabetes pilot project, directly advancing state budget allocation for healthcare initiatives.90% confidence ✓ HealthcareSupports HealthcareCreates Prescription Drug Affordability Review Board to lower costs, allocates $500k for operations/pilot, modifies Medicaid copays to improve affordability.95% confidence

Sub-Topics Appropriations Medicaid Prescription Drugs Primary Care

Track